Effects of adipose and bone marrow-derived mesenchymal stem cells on vaginal atrophy in a rat menopause model

Kasap, Burcu; Kasap, Şükrü; Vatansever, Seda; Kendirci, Remziye; Yılmaz, Osman; Çalışır, Meryem; Edgünlü, Tuba Gökdoğan; Akin, Melike Nur

doi:10.1016/j.gene.2019.06.027

Cited by 11 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Elde edilen süpernetant atıldı, pellet üzerine %10 FBS, %1 penisilin/streptomisin-amfoterisin B içeren DMEM/F12 besiyeri eklenerek hücreler 25cm2'lik flaskalara ekildi. 26 Hücrelerin kültür tabağına yapışıp çoğalması için beklendi. 3. ve 4. pasajdaki hücreler deney için kullanıldı.…”

Section: Yağ Doku Mezenkimal Kök Hücre Eldesiunclassified

Effects of adipose tissue derived mesenchymal stem cells and conditioned medium on experimental premature ovarian insufficiency model

Halicioğlu

Tuğlu

2021

Cukurova Medical Journal

View full text Add to dashboard Cite

The aim of this study was to investigate the effects of adipose tissue derived mesenchymal stem cells (ADMSC) and conditioned medium (CM), which can be recommended for the treatment of chemotherapy-induced premature ovarian insufficiency (POI), on oxidative stress and apoptosis. Materials and Methods: In the study, adult female Wistar albino rats were divided into 4 groups; Control, POI, POI+ADMSC, POI+CM. H&E staining was performed for histopathological evaluations in the ovary and all ovarian follicles were counted. iNOS and Caspase3 expressions were shown immunohistochemically as markers of oxidative stress and apoptosis. Results: Follicular cell degenerations and vacuolization were observed in the ovaries of the POI group, while significant decreases were observed in these degenerations in the ADMSC and CM groups. Increased iNOS and Caspase3 expressions in the POI group were statistically significant decreased in both the ADMSC and CM groups. Conclusion:Mesenchymal stem cells and cell-free conditioned medium, which are increasingly used in the field of regenerative medicine, can be an alternative treatment strategy for POI by reducing apoptosis and oxidative stress, which are the main mechanisms of the disease.Amaç: Kemoterapi kaynaklı prematür over yetmezliği (POY) tedavisi için önerilebilecek yağ doku mezenkimal kök hücreleri (YDMKH) ve bu hücrelerden elde edilmiş koşullu besiyerinin (KB) oksidatif stres ve apoptoz üzerine etkilerinin araştırılması amaçlandı. Gereç ve Yöntem: Çalışmada Wistar albino cinsi erişkin dişi sıçanlar 4 gruba ayrıldı. Kontrol, POY, POY+YDMKH, POY+KB. Ovaryumda histopatolojik değerlendirmeler için H&E boyamaları yapıldı ve tüm ovaryum folilkülleri sayıldı. Oksidatif stres ve apoptoz belirteci olarak iNOS ve Caspase3 ekspresyonları immunohistokimyasal olarak gösterildi. Bulgular: Analizler sonucu POY grubu ovaryumlarında foliküller hücre dejenerasyonları, vakuolizasyon, gibi dejenerasyonlar gözlenirken, YDMKH ve KB gruplarında bu dejenerasyonlarda anlamlı azalmalar görüldü. POY grubunda artmış olan iNOS ve Caspase3 ekspresyonları YDMKH ve KB gruplarının her ikisinde de istatistiksel olarak anlamlı şekilde azaldı. Sonuç: Rejeneratif tıp alanında her geçen gün kullanımı artan mezenkimal kök hücrelerin ve hücresiz koşullu besiyerinin prematür over yetmezliğinde hastalığın temel mekanizmalarından olan apoptoz ve oksidatif stresin azaltılması yoluyla, POY için alternatif bir tedavi stratejisi olabileceği gösterildi. Keywords:. premature ovarian insufficiency, adipose derived mesenchymal stem cell, conditioned medium, apoptosis, oxidative stress Anahtar kelimeler: prematür over yetmezliği, mezenkimal kök hücre, koşullu besiyeri, apoptoz, oksidatif stres GİRİŞ Mezenkimal kök hücreler (MKH), multipotent yetişkin kök hücrelerdir. Mezoderm kaynaklı olmalarına rağmen bu hücreler uygun koşullarda nöronlar dahil farklı birçok hücre tipine farklılaşabilme kapasitesine sahiptir 1 . Hücresel

show abstract

Section: Yağ Doku Mezenkimal Kök Hücre Eldesiunclassified

Effects of adipose tissue derived mesenchymal stem cells and conditioned medium on experimental premature ovarian insufficiency model

Halicioğlu

Tuğlu

2021

Cukurova Medical Journal

View full text Add to dashboard Cite

show abstract

“…ADMSCs are used in the field of regenerative medicine because they are easier to obtain in the form of body fat. ADMSCs may have regenerative and potentially therapeutic effects on postmenopausal vaginal atrophy by decreasing apoptosis (apoptosis of vaginal cells has been shown to increase atrophy) and angiogenesis [43].…”

Section: Can Stem Cells Improve the Outcome Of Covid-19?mentioning

confidence: 99%

Gyn-Aesthetic: the ‘new normal’ after COVID-19

Sánchez-Borrego¹,

García-Giménez²,

González-Isaza³

et al. 2020

Clin Obstet Gynecol Reprod Med

View full text Add to dashboard Cite

In the post-COVID-19 era, it will be important to better understand the host response to severe acute respiratory syndrome related to coronaviurus-2 (SARS-CoV-2) infection and the pathology of disease in genital tissue. A better understanding of how SARS-CoV-2 causes disease and how the host responds can help direct new therapeutic targets. With the arrival of the "new normal", women who want to start or who are already undergoing treatment require cosmetic, esthetic and/or functional gynecological procedures that have been safely and ethically modified. Given that there is a possibility of the pandemic re-emerging and that we do not know how the use of different techniques can affect the virus environment, we must take the lessons learned seriously in these unprecedented times, since the virus will not completely disappear from our society once the first wave of the pandemic ends.

show abstract

“…As a result, women with vaginal atrophy often suffer from vaginal dryness, itching, burning, and pain when urinating and during intercourse ( Naumova and Castelo-Branco 2018 ). ASCs and bone marrow-derived MSCs were able to improve epithelial thickness in a menopause rat model of vaginal atrophy with superior therapeutic effects in the former group ( Kasap et al, 2019 ). The expression of estrogen receptor, VEGF and its receptor was increased in vaginal epithelium and connective tissue after MSC administration ( Kasap et al, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

“…ASCs and bone marrow-derived MSCs were able to improve epithelial thickness in a menopause rat model of vaginal atrophy with superior therapeutic effects in the former group ( Kasap et al, 2019 ). The expression of estrogen receptor, VEGF and its receptor was increased in vaginal epithelium and connective tissue after MSC administration ( Kasap et al, 2019 ). Zhang et al performed in situ injection of umbilical cord-derived MSCs to repair fragile vaginal tissue in an ovariectomized rhesus macaque model ( Zhang et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

“…Inhibition of VEGF-A interfered with theca and granulosa cell proliferation, diminished follicular angiogenesis, disrupted ovulation, and led to miscarriage ( Wulff et al, 2001 ; Fraser et al, 2010 ). In a mouse model of vaginal atrophy, ASC administration induced increased expression of VEGF and its receptor in both connective tissue and the epithelial layer of the vagina in correlation with a higher anti-apoptotic factor bcl2 and reduced epithelial damage ( Kasap et al, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

“Adipose-derived mesenchymal stem cell therapy for the management of female sexual dysfunction: Literature reviews and study design of a clinical trial”

Hoang

Nguyen

Hoang

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Hormone imbalance and female sexual dysfunction immensely affect perimenopausal female health and quality of life. Hormone therapy can improve female hormone deficiency, but long-term use increases the risk of cardiovascular diseases and cancer. Therefore, it is necessary to develop a novel effective treatment to achieve long-term improvement in female general and sexual health. This study reviewed factors affecting syndromes of female sexual dysfunction and its current therapy options. Next, the authors introduced research data on mesenchymal stromal cell/mesenchymal stem cell (MSC) therapy to treat female reproductive diseases, including Asherman’s syndrome, premature ovarian failure/primary ovarian insufficiency, and vaginal atrophy. Among adult tissue-derived MSCs, adipose tissue-derived stem cells (ASCs) have emerged as the most potent therapeutic cell therapy due to their abundant presence in the stromal vascular fraction of fat, high proliferation capacity, superior immunomodulation, and strong secretion profile of regenerative factors. Potential mechanisms and side effects of ASCs for the treatment of female sexual dysfunction will be discussed. Our phase I clinical trial has demonstrated the safety of autologous ASC therapy for women and men with sexual hormone deficiency. We designed the first randomized controlled crossover phase II trial to investigate the safety and efficacy of autologous ASCs to treat female sexual dysfunction in perimenopausal women. Here, we introduce the rationale, trial design, and methodology of this clinical study. Because aging and metabolic diseases negatively impact the bioactivity of adult-derived MSCs, this study will use ASCs cultured in physiological oxygen tension (5%) to cope with these challenges. A total of 130 perimenopausal women with sexual dysfunction will receive two intravenous infusions of autologous ASCs in a crossover design. The aims of the proposed study are to evaluate 1) the safety of cell infusion based on the frequency and severity of adverse events/serious adverse events during infusion and follow-up and 2) improvements in female sexual function assessed by the Female Sexual Function Index (FSFI), the Utian Quality of Life Scale (UQOL), and the levels of follicle-stimulating hormone (FSH) and estradiol. In addition, cellular aging biomarkers, including plasminogen activator inhibitor-1 (PAI-1), p16 and p21 expression in T cells and the inflammatory cytokine profile, will also be characterized. Overall, this study will provide essential insights into the effects and potential mechanisms of ASC therapy for perimenopausal women with sexual dysfunction. It also suggests direction and design strategies for future research.

show abstract

Effects of adipose and bone marrow-derived mesenchymal stem cells on vaginal atrophy in a rat menopause model

Cited by 11 publications

References 28 publications

Effects of adipose tissue derived mesenchymal stem cells and conditioned medium on experimental premature ovarian insufficiency model

Effects of adipose tissue derived mesenchymal stem cells and conditioned medium on experimental premature ovarian insufficiency model

Gyn-Aesthetic: the ‘new normal’ after COVID-19

“Adipose-derived mesenchymal stem cell therapy for the management of female sexual dysfunction: Literature reviews and study design of a clinical trial”

Contact Info

Product

Resources

About